Biotech focused on pulmonary hypertension drugs, also developing gene-edited pig organs for human transplantation.
Biotech focused on pulmonary hypertension drugs, also developing gene-edited pig organs for human transplantation.
Earns most of its revenue from drugs built on one molecule, treprostinil, given by inhaler, pill or infusion for pulmonary arterial hypertension (high blood pressure in the lung arteries). The organ work, run through its subsidiary Revivicor, is funded from those drug sales and has no product revenue yet. It is organised as a public benefit corporation.
Moat: narrow (IP / patents, regulatory licence). Established leadership in a niche rare-disease category (PAH) with patent-protected drug formulations.
Headquarters: Silver Spring, Maryland, US · Founded: 1996 · Employees: 1,400
Size United Therapeutics (UTHR) is a United States Health Care company (Biotechnology) with a market value of $24.6B, the 429th largest of 3,085 United States companies the cockpit tracks. Shares closed at $577.34 on 18 Nov 2026.
Performance Over six months the shares gained 2.4%, against +31.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +20.8%); the operating margin is 43.6% (peer median 24.6%).
Valuation It trades at 23.9× forward earnings against a peer median of 27.7× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.6 points above its cost of capital (7.5% WACC).
Short interest Short interest is 4.3% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.19B | $3.18B | $2.88B | $2.33B | $1.94B |
| Revenue growth | — | +11% | +24% | +20% | — |
| Gross profit | $2.75B | $2.80B | $2.57B | $2.07B | $1.78B |
| EBITDA | $1.48B | $1.60B | $1.45B | $1.24B | $1.04B |
| Net income | $1.23B | $1.33B | $1.20B | $985M | $727M |
| Free cash flow | $864M | $1.04B | $1.08B | $748M | $656M |
| Capital expenditure | $562M | $526M | $246M | $230M | $139M |
| Total debt | $0 | $0 | $300M | $700M | $800M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| United Therapeutics UTHR | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| Liquidia LQDA | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | UTHR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.2% | +0.9% | 10th highest of 21 |
| 6-month return | +2.4% | +31.4% | 3rd lowest of 21 |
| Distance from 52-week high | -6.0% | -14.3% | 5th highest of 21 |
| Revenue growth (TTM) | +1.9% | +20.8% | 7th lowest of 21 |
| Operating margin | 43.6% | 24.6% | 3rd highest of 21 |
| Forward P/E | 23.9× | 27.7× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 11.1% | 4th least demanding of 17 |
| Growth delivered (Del g) | +16.5% | +14.8% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | -16.2 pp | -7.5 pp | 5th least demanding of 17 |
| ROIC minus cost of capital | +18.6 pp | +1.3 pp | 5th highest of 21 |
| EV / EBITDA | 15.2× | 16.7× | 4th cheapest of 16 |
| Net debt / EBITDA | -1.4× | 1.2× | 4th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| United Therapeutics UTHR | United States | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $23.1B | +35% | +22% | 32% | 26.5× | 20.8% | +30.2% |
| BioNTech SE Sponsored ADR BNTX | United States | $20.6B | -8% | -21% | -61% | n/a | n/a | n/a |
| Genmab A/S GMAB.CO | Denmark | $30.8B | +103% | +15% | 31% | 40.9× | 11.6% | +19.5% |
| Celltrion 068270.KS | South Korea | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% | +17.6% |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% | +22.3% |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |
| Natera NTRA | United States | $42.0B | +41% | +37% | -9% | n/a | n/a | n/a |
| Iqvia IQV | United States | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% | +7.5% |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Samsung Biologics 207940.KS | South Korea | $48.7B | -6% | -20% | 43% | 34.4× | 7.0% | +31.4% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| Lonza LONN.SW | Switzerland | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% | +7.7% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 29.0× | 11.7% | +151.4% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| CSL CSL.AX | Australia | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% | +11.0% |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |